Results 31 to 40 of about 16,411 (192)
Drugs in Context, 2023 Edoxaban, a once-daily, direct-acting oral anticoagulant, is approved to prevent stroke or systemic embolism in non-valvular atrial fibrillation (NVAF) and treat venous thromboembolism.
Alejandro Bimbo Diaz +8 more
doaj +1 more source
Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. [PDF]
, 2019 AIMS: Edoxaban is a direct factor Xa inhibitor approved for stroke prevention in atrial fibrillation (AF). Uninterrupted edoxaban therapy in patients undergoing AF ablation has not been tested. METHODS AND RESULTS: The ELIMINATE-AF trial, a multinational,
Abozguia, K +13 more
core +2 more sources
An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. [PDF]
, 2015 Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant morbidity and mortality from cardioembolic complications like stroke.
Acharya, Tushar, Deedwania, Prakash
core +1 more source
Thrombosis Journal, 2019 Background This study involved a sensory evaluation of edoxaban orally disintegrating (OD) tablets in patients with nonvalvular atrial fibrillation who had been receiving the existing edoxaban film-coated tablets before the study.
Takeshi Yamashita +5 more
doaj +1 more source
Physiological Reports, 2022 Chronic kidney disease (CKD) is an increasing and life‐threatening disease worldwide. Recent evidence indicates that blood coagulation factors promote renal dysfunction in CKD patients.
Lixin Fang +11 more
doaj +1 more source
Managing patients taking edoxaban in dentistry [PDF]
, 2017 Anticoagulation therapy is used in several conditions to prevent or treat thromboembolism. A new group of oral anticoagulants with clear advantages over classic dicoumarin oral anticoagulants (warfarin and acenocoumarol) has been developed in recent ...
Curto Aguilera, Adrián +2 more
core +1 more source
Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]
, 2018 © 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki +3 more
core +2 more sources
Edoxaban use in the context of dental procedures: analysis from the EMIT-AF/VTE database
BDJ Open, 2023 Introduction Literature reviews support continuing anticoagulation during dental procedures. However, studies often present grouped anticoagulation data, and information on individual anticoagulant management would be helpful to dentists.
Cathy Chen +9 more
doaj +1 more source
Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation:systematic review, network meta-analysis and cost-effectiveness analysis [PDF]
, 2017 BACKGROUND: Warfarin is effective for stroke prevention in atrial fibrillation (AF), but anticoagulation is underused in clinical care. The risk of venous thromboembolic disease during hospitalisation can be reduced by low-molecular-weight heparin (LMWH):
Sterne, Jonathan Ac +17 more
core +3 more sources